Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials

OBJECTIVE: Previous studies showed that the combination of bevacizumab and erlotinib (combination therapy) significantly prolonged progression-free survival (PFS) but no overall survival (OS) compared to erlotinib alone (monotherapy) for advanced EGFR-mutant non-small cell lung cancer (NSCLC). Two p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ruijian, Li, Weiyi, Zhang, Fang, Li, Shanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463988/
https://www.ncbi.nlm.nih.gov/pubmed/37635242
http://dx.doi.org/10.1186/s40001-023-01272-7